All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction.

Department of Biochemistry, Weill Medical College of Cornell University, New York, NY 10021, USA.
Journal of Cell Science (Impact Factor: 5.33). 03/2002; 115(Pt 4):679-88.
Source: PubMed

ABSTRACT The tumor necrosis factor (TNF) receptor associated factors (TRAFs) have emerged as the major signal transducers for the TNF receptor superfamily and the interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) superfamily. TRAFs collectively play important functions in both adaptive and innate immunity. Recent functional and structural studies have revealed the individuality of each of the mammalian TRAFs and advanced our understanding of the underlying molecular mechanisms. Here, we examine this functional divergence among TRAFs from a perspective of both upstream and downstream TRAF signal transduction pathways and of signaling-dependent regulation of TRAF trafficking. We raise additional questions and propose hypotheses regarding the molecular basis of TRAF signaling specificity.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Renal cell carcinoma (RCC) is the commonest of the renal neoplasms. Although surgery and cryoablation are successful curative treatments for localized RCC, most patients are diagnosed with advanced or metastatic RCC, which has a poor prognosis. RCC are a heterogeneous set of cancers that have traditionally been classified and staged using cellular characteristics, size, local extension and distant metastases. Current staging systems provide good prognostic information, but it is very likely that the identification of new more accurate and predictive prognostic markers, not currently included in traditional staging systems, will improve the outcome for RCC patients. For this reason, increased knowledge of the underlying molecular characteristics of RCC development and progression is necessary. In most cancers, but especially RCC, deregulated control of apoptosis contributes to cancer growth by aberrantly extending cell viability and facilitating resistance to cancer therapies. Here we present the hypothesis that select members of the tumor necrosis factor (TNF) superfamily, the TNF receptor-associated factors (TRAFs), have a role in RCC apoptosis and may have prognostic significance for RCC. Candidate biomarkers for RCC are few, and the TRAFs may be important inclusions in panels of biomarkers for RCC. TRAFs may also be potential molecular targets for new therapies, either through their ability to promote apoptosis in the cancers themselves, or through their ability to modulate the immune defence against cancer progression. Some support data are presented here for our hypothesis. However, these novel concepts need further careful analysis to allow clinicians and oncologists any assistance for earlier detection of RCC and for characterizing patients with RCC for individualised targeted therapy.
    Medical Hypotheses 12/2011; 78(2):330-6. DOI:10.1016/j.mehy.2011.11.014 · 1.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) is a key signaling adaptor protein not only for the TNFR superfamily but also for the Interleukin-1 receptor/Toll-like receptor (IL-1/TLR) superfamily. To investigate TRAF6 function in invertebrate innate immune responses, Litopenaeus vannamei TRAF6 (LvTRAF6) was identified and characterized. The full-length cDNA of LvTRAF6 is 2823bp long, with an open reading frame (ORF) encoding a putative protein of 594 amino acids, including a RING-type Zinc finger, two TRAF-type Zinc fingers, a coiled-coil region, and a meprin and TRAF homology (MATH) domain. The overall amino acid sequence identity between LvTRAF6 and other known TRAF6s is 22.2-33.3%. Dual luciferase reporter assays in Drosophila S2 cells revealed that LvTRAF6 could activate the promoters of antimicrobial peptide genes (AMPs), including Drosophila Attacin A and Drosomycin, and shrimp Penaeidins. Real-time quantitative PCR (qPCR) indicated that LvTRAF6 was constitutively expressed in various tissues of L. vannamei. After Vibrio alginolyticus and white spot syndrome virus (WSSV) challenge, LvTRAF6 was down-regulated, though with different expression patterns in the intestine compared to other tissues. After WSSV challenge, LvTRAF6 was up-regulated 2.7- and 2.3-fold over the control at 3h in gills and hepatopancreas, respectively. These results indicated that LvTRAF6 may play a crucial role in antibacterial and antiviral responses via regulation of AMP gene expression.
    Developmental and comparative immunology 01/2011; 35(1):105-14. DOI:10.1016/j.dci.2010.08.013 · 3.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In many physiological and disease processes, TGF-beta usurps branches of MAP kinase pathways in conjunction with Smads to induce apoptosis and epithelial-to-mesenchymal transition, but the detailed mechanism of how a MAP kinase cascade is activated by TGF-beta receptors is not clear. We report here that TRAF6 is specifically required for the Smad-independent activation of JNK and p38, and its carboxyl TRAF homology domain physically interacts with TGF-beta receptors. TGF-beta induces K63-linked ubiquitination of TRAF6 and promotes association between TRAF6 and TAK1. Our results indicate that TGF-beta activates JNK and p38 through a mechanism similar to that operating in the interleukin-1beta/Toll-like receptor pathway.
    Molecular cell 10/2008; 31(6):918-24. DOI:10.1016/j.molcel.2008.09.002 · 14.46 Impact Factor


1 Download
Available from